CATCH-UP GROWTH DURING TOCILIZUMAB THERAPY FOR SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS: 2-YEAR DATA FROM A PHASE 3 CLINICAL TRIAL

被引：0
|
作者：
De Benedetti, F. [1 ]
Ruperto, N. [2 ]
Espada, G. [2 ]
Gerloni, V. [2 ]
Flato, B. [3 ]
Horneff, G. [2 ]
Myones, B. [4 ]
Onel, K. [4 ]
Frane, J.
Wang, J. [5 ]
Lipman, T. [6 ]
Bharucha, K. [7 ]
Martini, A. [2 ]
Lovell, D. [4 ]
机构：
[1] IRCCS Osped Pediat Bambino Gesu, Rome, Italy
[2] PRINTO, Genoa, Italy
[3] OUS, Oslo, Norway
[4] PRCSG, Cincinnati, OH USA
[5] Roche, Welwyn Garden City, England
[6] U Penn Sch Nursing, Philadelphia, PA USA
[7] Genentech Inc, San Francisco, CA 94080 USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2013年 / 72卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：729 / 730
页数：2
相关论文
共 50 条
  • [31] PReS-FINAL-2180: Efficacy and safety of tocilizumab (TCZ) in patients with polyarticular-course juvenile idiopathic arthritis (pcJIA): 2-year data from CHERISH
    F De Benedetti
    N Ruperto
    Z Zuber
    R Cuttica
    R Xavier
    I Calvo
    N Rubio
    E Alekseeva
    V Chasnyk
    J Chavez
    G Horneff
    V Opoka-Winiarska
    P Quartier
    A Spindler
    C Keane
    K Bharucha
    J Wang
    D Lovell
    A Martini
    HI Brunner
    [J]. Pediatric Rheumatology, 11 (Suppl 2)
  • [32] Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan
    Yokota, Shumpei
    Itoh, Yasuhiko
    Morio, Tomohiro
    Origasa, Hideki
    Sumitomo, Naokata
    Tomobe, Minako
    Tanaka, Kunihiko
    Minota, Seiji
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 (09) : 1654 - 1660
  • [33] Tocilizumab Is efficacious in patients with Systemic Juvenile Idiopathic Arthritis (sJIA) across baseline disease characteristics and prior/baseline treatments: 12-week data from the Phase 3 TENDER Trial
    Ruperto, N.
    De Benedetti, F.
    Brunner, H.
    Allen, R.
    Brown, D.
    Chaitow, J.
    Cortis, E.
    Espada, G.
    Flato, B.
    Gerloni, V.
    Horneff, G.
    Wright, S.
    Kenwright, A.
    Schneider, R.
    Woo, P.
    Martini, A.
    Lovell, D.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2011, 29 (02) : 370 - 371
  • [34] Catch-up growth in severe systemic-onset juvenile idiopathic arthritis: Long-term treatment with humanized anti-IL6 receptor monoclonal antibody
    Imagawa, T
    Miyamae, T
    Umebayashi, H
    Kurosawa, R
    Katakura, S
    Mori, M
    Nishimoto, N
    Yokota, S
    Kishimoto, T
    [J]. ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S91 - S92
  • [35] DISABILITY AND HEALTH-RELATED QUALITY OF LIFE OUTCOMES IN PATIENTS WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS TREATED WITH TOCILIZUMAB IN A PHASE 3 RANDOMIZED CONTROLLED TRIAL
    Ruperto, Nicolino
    Chen, Chen
    Martini, Alberto
    Espada, Graciela
    Joos, Rik
    Akikusa, Jonathan
    Chaitow, Jeffrey
    Gamir, Maria Luz Gamir
    Kimura, Yukiko
    Rietschel, Christoph
    Siri, Daniel
    Smolewska, Elzbieta
    Schmeling, Heinrike
    Brown, Diane
    De Benedetti, Fabrizio
    Lovell, Daniel J.
    Huang, Bin
    Brunner, Hermine
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 981 - 982
  • [36] Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: results from an open-label phase 1 clinical trial
    Mallalieu, Navita L.
    Wimalasundera, Sunethra
    Hsu, Joy C.
    Douglass, Wendy
    Wells, Chris
    Penades, Inmaculada Calvo
    Cuttica, Ruben
    Huppertz, Hans-Iko
    Joos, Rik
    Kimura, Yukiko
    Milojevic, Diana
    Rosenkranz, Margalit
    Schikler, Kenneth
    Constantin, Tamas
    Wouters, Carine
    [J]. PEDIATRIC RHEUMATOLOGY, 2019, 17 (01)
  • [37] Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: results from an open-label phase 1 clinical trial
    Navita L. Mallalieu
    Sunethra Wimalasundera
    Joy C. Hsu
    Wendy Douglass
    Chris Wells
    Inmaculada Calvo Penades
    Ruben Cuttica
    Hans-Iko Huppertz
    Rik Joos
    Yukiko Kimura
    Diana Milojevic
    Margalit Rosenkranz
    Kenneth Schikler
    Tamas Constantin
    Carine Wouters
    [J]. Pediatric Rheumatology, 17
  • [38] Effect of long-acting PEGylated growth hormone for catch-up growth in children with idiopathic short stature: a 2-year real-world retrospective cohort study
    Xie, Liulu
    Li, Yanhong
    Zhang, Jun
    Guo, Song
    Chen, Qiuli
    Ma, Huamei
    Jiang, Wenjun
    [J]. EUROPEAN JOURNAL OF PEDIATRICS, 2024,
  • [39] EVALUATION OF EFFICACY AND SAFETY OF CANAKINUMAB IN JAPANESE PATIENTS WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS IN PHASE III CLINICAL TRIAL, COMPOSED PREDOMINANTLY OF PATIENTS WITH PRIOR USE OF TOCILIZUMAB
    Takei, S.
    Hara, R.
    Umebayashi, H.
    Iwata, N.
    Imagawa, T.
    Shimizu, M.
    Tomiita, M.
    Seko, N.
    Kitawaki, T.
    Wang, G.
    Yokota, S.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 499 - 500
  • [40] Predictive factors and biomarkers for the 2-year outcome of uveitis in juvenile idiopathic arthritis: data from the Inception Cohort of Newly diagnosed patients with Juvenile Idiopathic Arthritis (ICON-JIA) study
    Heiligenhaus, Arnd
    Klotsche, Jens
    Tappeiner, Christoph
    Sengler, Claudia
    Niewerth, Martina
    Liedmann, Ina
    Hoeft, Sabine
    Walscheid, Karoline
    Lavric, Miha
    Foell, Dirk
    Minden, Kirsten
    [J]. RHEUMATOLOGY, 2019, 58 (06) : 975 - 986
12345